Prevalence, predictors, and clinical relevance of drug–drug interactions in outpatient prescribing: A national cross-sectional study
PLOS One · 2026
DOI: 10.1371/journal.pone.0345076 ↗Kurz gefasst
Querschnittstudie in der Zeitschrift PLOS One, 2026. Verfasst von Seyed Sahab Aarabi und 7 weiteren Autor:innen. Beteiligte Einrichtung: National Center for Health Insurance Research, Tehran, Iran. Hauptthemen laut MEDLINE: Drug Interactions, Drug Prescriptions, Ambulatory Care. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 69 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Drug–drug interactions (DDIs) represent a major preventable cause of medication-related harm globally. Their prevalence varies across health systems, but common drivers include polypharmacy, aging populations, and specialty-specific prescribing patterns. Large-scale pharmacoepidemiologic analyses of real-world prescription data can clarify the magnitude of the problem and inform strategies to reduce risks.
Methods
This retrospective study included 2,365,811 outpatient prescriptions (982,102 patients) from Tehran, Iran. The top 100 most prescribed medications were screened for potential DDIs via Micromedex®. Interactions were classified as contraindicated, major, or moderate. Logistic regression identified demographic, specialty, and prescription-level predictors.
Results
Potential DDIs occurred in 46.1% of prescriptions, with 57.8% of patients affected. Major DDIs (62.6%) dominated, followed by moderate (32.8%) and contraindicated (4.6%). ASA was a frequent contributor to high-risk pairs. Contraindicated interactions were largely NSAID duplications, most common in orthopedics and emergency medicine. Psychiatry and cardiology prescriptions showed the highest prevalence, while polypharmacy strongly predicted DDIs, with incremental risks amplified in older adults.
Conclusions
Outpatient DDIs represent a substantial burden in routine care, comparable to international reports. Prevention requires comprehensive strategies, including e-prescribing with CDSS, pharmacist-led reviews, patient education on OTC use, and policy interventions to limit reimbursement of unsafe combinations.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- National Center for Health Insurance Research, Tehran, Iran.
- School of Medicine, Tehran University of Medical Sciences (TUMS), Tehran, Iran.
- School of Medicine, Shahid Beheshti University of Medical Sciences (SBMU), Tehran, Iran.
- Endometriosis Research Center, Iran University of Medical Sciences (IUMS), Tehran, Iran.
- Clinical Research Development Unit, Yasuj University of Medical Sciences, Yasuj, Iran.
- Behbahan Faculty of Medical Sciences, Behbahan, Iran.
ORCID-Profile: Seyed Sahab Aarabi, Farbod Semnani, Zahra Aminzade, Leila Ghamkhar
Zitieren
APA
Aarabi, S. S., Semnani, F., Aminzade, Z., Mehrizi, R., Gholamnezhad, M., Armand, R., Armand, N., & Ghamkhar, L. (2026). Prevalence, predictors, and clinical relevance of drug–drug interactions in outpatient prescribing: A national cross-sectional study. PLOS One. https://doi.org/10.1371/journal.pone.0345076
Vancouver
Aarabi SS, Semnani F, Aminzade Z, Mehrizi R, Gholamnezhad M, Armand R, et al. Prevalence, predictors, and clinical relevance of drug–drug interactions in outpatient prescribing: A national cross-sectional study. PLOS One. 2026. doi:10.1371/journal.pone.0345076
BibTeX
@article{Aarabi2026,
author = {Aarabi, Seyed Sahab and Semnani, Farbod and Aminzade, Zahra and Mehrizi, Reza and Gholamnezhad, Mohammad and Armand, Raham and Armand, Nezam and Ghamkhar, Leila},
title = {Prevalence, predictors, and clinical relevance of drug–drug interactions in outpatient prescribing: A national cross-sectional study},
journal = {PLOS One},
year = {2026},
doi = {10.1371/journal.pone.0345076}
}
EUVIMED